The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Favorable Anakinra Responses in Severe Covid-19 Patients with Secondary Hemophagocytic Lymphohistiocytosis
Open accessAbstract
Dysregulation of inflammation is hypothesized to play a crucial role in the severe complications of COVID-19, with the IL-1/IL-6 pathway being central. Here, we report on the treatment of eight severe COVID-19 pneumonia patients—seven hospitalized in intensive care units (ICUs) in Greece and one non-ICU patient in the Netherlands—with the interleukin-1 receptor antagonist Anakinra. All patients scored positive for the hemophagocytosis score (HScore) and were diagnosed with secondary hemophagocytic lymphohistocytosis (sHLH) characterized by pancytopenia, hyper-coagulation, acute kidney injury, and hepatobiliary dysfunction. At the end of treatment, ICU patients had less need for vasopressors, significantly improved respiratory function, and lower HScore. Although three patients died, the mortality was lower than historical series of patients with sHLH in sepsis. These data suggest that administration of Anakinra may be beneficial for treating severe COVID-19 patients with sHLH as determined by the HScore, and they support the need for larger clinical studies to validate this concept.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Chen, N., Zhou, M., Dong, X., Qu, J., Gong, F., Han, Y., Qiu, Y., Wang, J., Liu, Y., Wei, Y., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30211-7 · Cited by 21,415
Dysregulation of Immune Response in Patients With Coronavirus 2019 (COVID-19) in Wuhan, China
Qin, C., Zhou, L., Hu, Z., Zhang, S., Yang, S., Tao, Y., Xie, C., Ma, K., Shang, K., Wang, W., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa248 · Cited by 4,775 · cited 1×
“The cytokine storm described in these patients (Qin et al., 2020) introduced the concept of attenuation of the hyper-inflammation, with agents targeting pro-inflammatory cytokines, mainly interleukin (IL)-1b and IL-6.”
Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study
Chen, T., Wu, D., Chen, H., Yan, W., Yang, D., Chen, G., Ma, K., Xu, D., Yu, H., Wang, H., et al. (2020) · BMJ · doi:10.1136/bmj.m1091 · Cited by 3,903
Shakoory, B., Carcillo, J. A., Chatham, W. W., Amdur, R. L., Zhao, H., Dinarello, C. A., Cron, R. Q., & Opal, S. M. (2016) · Critical Care Medicine · doi:10.1097/ccm.0000000000001402 · Cited by 867
Cited by
Severe COVID-19 Is Marked by a Dysregulated Myeloid Cell Compartment
Schulte-Schrepping, J., Reusch, N., Paclik, D., Baßler, K., Schlickeiser, S., Zhang, B., Krämer, B., Krammer, T., Brumhard, S., Bonaguro, L., et al. (2020) · Cell · doi:10.1016/j.cell.2020.08.001 · Cited by 1,461
“Mitigation of immunodysregulation is therefore viewed as amajor therapeutic avenue for the treatment andprevention of severe COVID-19 (Dimopoulos et al., 2020; Jamilloux et al., 2020).”
COVID-19 and diabetes mellitus: from pathophysiology to clinical management
Lim, S., Bae, J. H., Kwon, H.-S., & Nauck, M. A. (2021) · Nature Reviews Endocrinology · doi:10.1038/s41574-020-00435-4 · Cited by 1,006
Immunity, endothelial injury and complement-induced coagulopathy in COVID-19
Perico, L., Benigni, A., Casiraghi, F., Ng, L. F. P., Renia, L., & Remuzzi, G. (2021) · Nature Reviews Nephrology · doi:10.1038/s41581-020-00357-4 · Cited by 607
The signal pathways and treatment of cytokine storm in COVID-19
Yang, L., Xie, X., Tu, Z., Fu, J., Xu, D., & Zhou, Y. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00679-0 · Cited by 603
The unique characteristics of COVID-19 coagulopathy
Iba, T., Levy, J. H., Connors, J. M., Warkentin, T. E., Thachil, J., & Levi, M. (2020) · Critical Care · doi:10.1186/s13054-020-03077-0 · Cited by 533
Henderson, L. A., Canna, S. W., Friedman, K. G., Gorelik, M., Lapidus, S. K., Bassiri, H., Behrens, E. M., Ferris, A., Kernan, K. F., Schulert, G. S., et al. (2020) · Arthritis & Rheumatology · doi:10.1002/art.41454 · Cited by 531
The COVID-19 puzzle: deciphering pathophysiology and phenotypes of a new disease entity
Osuchowski, M. F., Winkler, M. S., Skirecki, T., Cajander, S., Shankar-Hari, M., Lachmann, G., Monneret, G., Venet, F., Bauer, M., Brunkhorst, F. M., et al. (2021) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(21)00218-6 · Cited by 520
Self-citationCOVID-19 Associated Pulmonary Aspergillosis (CAPA)—From Immunology to Treatment
Arastehfar, A., Carvalho, A., van de Veerdonk, F. L., Jenks, J. D., Koehler, P., Krause, R., Cornely, O. A., S. Perlin, D., Lass-Flörl, C., & Hoenigl, M. (2020) · Journal of Fungi · doi:10.3390/jof6020091 · Cited by 421
Self-citationHenderson, L. A., Canna, S. W., Friedman, K. G., Gorelik, M., Lapidus, S. K., Bassiri, H., Behrens, E. M., Ferris, A., Kernan, K. F., Schulert, G. S., et al. (2021) · Arthritis & Rheumatology · doi:10.1002/art.41616 · Cited by 412
Ferritin in the coronavirus disease 2019 (COVID‐19): A systematic review and meta‐analysis
Cheng, L., Li, H., Li, L., Liu, C., Yan, S., Chen, H., & Li, Y. (2020) · Journal of Clinical Laboratory Analysis · doi:10.1002/jcla.23618 · Cited by 387
Cavalli, G., Colafrancesco, S., Emmi, G., Imazio, M., Lopalco, G., Maggio, M. C., Sota, J., & Dinarello, C. A. (2021) · Autoimmunity Reviews · doi:10.1016/j.autrev.2021.102763 · Cited by 346
An immune-based biomarker signature is associated with mortality in COVID-19 patients
Abers, M. S., Delmonte, O. M., Ricotta, E. E., Fintzi, J., Fink, D. L., de Jesus, A. A. A., Zarember, K. A., Alehashemi, S., Oikonomou, V., Desai, J. V., et al. (2021) · JCI Insight · doi:10.1172/jci.insight.144455 · Cited by 340
Pharmaco-Immunomodulatory Therapy in COVID-19
Rizk, J. G., Kalantar-Zadeh, K., Mehra, M. R., Lavie, C. J., Rizk, Y., & Forthal, D. N. (2020) · Drugs · doi:10.1007/s40265-020-01367-z · Cited by 288
Tharaux, P.-L., Pialoux, G., Pavot, A., Mariette, X., Hermine, O., Resche-Rigon, M., Porcher, R., Ravaud, P., Bureau, S., Dougados, M., et al. (2021) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(20)30556-7 · Cited by 284
Disease severity-specific neutrophil signatures in blood transcriptomes stratify COVID-19 patients
(DeCOI), G. C.-1. O. I., Aschenbrenner, A. C., Mouktaroudi, M., Krämer, B., Oestreich, M., Antonakos, N., Nuesch-Germano, M., Gkizeli, K., Bonaguro, L., Reusch, N., et al. (2021) · Genome Medicine · doi:10.1186/s13073-020-00823-5 · Cited by 255
Self-citationAnakinra treatment in critically ill COVID-19 patients: a prospective cohort study
the RCI-COVID-19 Study Group, Kooistra, E. J., Waalders, N. J. B., Grondman, I., Janssen, N. A. F., de Nooijer, A. H., Netea, M. G., van de Veerdonk, F. L., Ewalds, E., van der Hoeven, J. G., et al. (2020) · Critical Care · doi:10.1186/s13054-020-03364-w · Cited by 119
Self-citation
Metadata
- Authors
- Dimopoulos, G., de Mast, Q., Markou, N., Theodorakopoulou, M., Komnos, A., Mouktaroudi, M., Netea, M. G., Spyridopoulos, T., Verheggen, R. J., Hoogerwerf, J., Lachana, A., van de Veerdonk, F. L., & Giamarellos-Bourboulis, E. J.
- Venue
- Cell Host & Microbe
- Publisher
- Elsevier BV
- Published
- 2020-07
- Volume
- 28
- Issue
- 1
- Pages
- 117-123.e1
- ISSN
- 1931-3128 (ISSN-L)
- OpenAlex
- W3025045885
- Cited by
- 245
- References
- 4
- FWCI
- 6.91
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.